SpliSense Cystic Fibrosis Drug Undergoes Clinical Trials
The FDA has granted orphan drug designation to the SpliSense cystic fibrosis drug SPL84-23, an ASO (antisense oligonucleotide).
The FDA has granted orphan drug designation to the SpliSense cystic fibrosis drug SPL84-23, an ASO (antisense oligonucleotide).